FIELD: medicine.
SUBSTANCE: invention relates to isolated polypeptides that are glucagon receptor-selective analogues, and their peptide derivatives. Such analogues are selective to a human glucagon receptor with improved solubility, thermal stability, as well as physical-chemical properties compared to native endogenous glucagon. The present invention also relates to methods for the use of such polypeptides for various therapeutic and diagnostic indications, as well as methods for obtaining such polypeptides.
EFFECT: such analogues are useful in the form of monotherapy or in combination with other therapeutic peptides in the treatment of obesity, various types of diabetes, metabolic disorders or diseases.
18 cl, 21 dwg, 8 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| PEPTIDE PRO-DRUGS OF AMIDE GLUCAGON SUPERFAMILY | 2011 |
|
RU2580317C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| METHOD OF TREATING INSULIN-INDEPENDENT DIABETES AND OBESITY, OSMOTIC DELIVERY SYSTEM AND METHOD FOR MAKING IT | 2008 |
|
RU2440097C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
